Ultragenyx, Mereo’s bone disease drug fails second interim analysis, stocks plummet
Ultragenyx Pharmaceutical and Mereo BioPharma’s antibody for a rare bone disease failed a second interim analysis in its pivotal trial, the companies
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.